6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
SIGNATURES
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Mr L Miels | |
| b) | Position/status | Chief Commercial Officer | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br> <br><br><br>ISIN: GB0009252882 | |
| b) | Nature<br>of the transaction | Following the vesting on 4 September 2021 of 25% of an award made<br>on 14 February 2018 under the GlaxoSmithKline Deferred Investment<br>Award Programme, Mr Miels will receive a cash payment of<br>409,730.64 less applicable tax withholding in respect of<br>27,706.968 notional Ordinary Shares. | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 27,706.968 | |||
| d) | Aggregated<br>information | N/A (single transaction) | |
| Aggregated<br>volume<br><br><br>Price | |||
| e) | Date<br>of the transaction | 2021-09-04 | |
| f) | Place<br>of the transaction | N/A |
All values are in British Pounds.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: September<br>07, 2021 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |